Working… Menu
Trial record 7 of 21 for:    SOGUG

Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib (Spazo-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03091465
Recruitment Status : Completed
First Posted : March 27, 2017
Last Update Posted : April 26, 2018
Information provided by (Responsible Party):
Spanish Oncology Genito-Urinary Group